Chen Sixun, Liu Dan
Biomanufacturing Technology, Bioprocessing Technology Institute (BTI), Agency for Science, Technology, and Research (A*STAR), 20 Biopolis Way, 138668, Singapore.
Biomanufacturing Technology, Bioprocessing Technology Institute (BTI), Agency for Science, Technology, and Research (A*STAR), 20 Biopolis Way, 138668, Singapore.
Trends Biotechnol. 2025 Apr;43(4):745-748. doi: 10.1016/j.tibtech.2024.09.013. Epub 2024 Oct 9.
The accessibility of autologous chimeric antigen receptor T cell (CAR-T) therapies is challenged by the complex processes and capacity constraints of manufacturing. Rapid manufacturing capable of shortening manufacturing timelines could transform the CAR-T field. Here, we outline approaches to rapid CAR-T manufacturing, highlighting its impact on various stakeholders in the landscape.
自体嵌合抗原受体T细胞（CAR-T）疗法的可及性受到制造过程复杂和产能限制的挑战。能够缩短制造时间线的快速制造可能会改变CAR-T领域。在此，我们概述了快速CAR-T制造的方法，强调了其对该领域各利益相关方的影响。
